United States Patent 9,895,388: A Detailed Analysis of Scope and Claims
Introduction
United States Patent 9,895,388, titled "Methods and compositions useful for controlling cutaneous mites," is a significant patent in the field of dermatology and parasitology. This patent, issued to Merck Sharp & Dohme Corp., addresses innovative methods and compositions for treating infestations caused by cutaneous mites, such as scabies and mange. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
Patent Title and Number
- Patent Number: US9895388
- Patent Title: Methods and compositions useful for controlling cutaneous mites
Patent Expiry
The patent is set to expire in November 2033, providing the patent holder with exclusive rights to the invention for nearly a decade from its issuance in 2018[1].
Scope of the Patent
Technical Field
The patent pertains to the field of pharmaceuticals and dermatology, specifically focusing on treatments for cutaneous mite infestations. It encompasses methods and compositions that target these parasites effectively.
Background
Cutaneous mites, such as Sarcoptes scabiei, cause significant discomfort and health issues. Traditional treatments often have limitations, including resistance development and side effects. This patent aims to address these challenges by introducing new methods and compositions.
Claims of the Patent
Independent Claims
The patent includes several independent claims that define the scope of the invention. These claims typically cover:
- Compositions: Specific formulations containing active ingredients effective against cutaneous mites.
- Methods: Treatment protocols and administration methods for these compositions.
- Uses: The therapeutic applications of these compositions and methods[1].
Dependent Claims
Dependent claims further specify and narrow down the scope of the independent claims. For example, they might detail specific concentrations of active ingredients, particular modes of administration (e.g., topical or oral), or specific patient populations (e.g., pediatric or geriatric)[3].
Key Components of the Patent
Active Ingredients
The patent specifies certain compounds and their derivatives that are effective against cutaneous mites. These compounds are often produced through fermentation or synthetic processes, highlighting the innovative approach to drug development[1].
Formulations
The patent describes various formulations, including creams, ointments, and oral tablets, designed to enhance the efficacy and safety of the treatment. These formulations are optimized for different patient needs and preferences.
Administration Methods
The methods of administration are a critical aspect of the patent. It includes detailed protocols for applying topical treatments and administering oral medications, ensuring maximum efficacy and minimal side effects.
Patent Landscape
Related Patents
Several related patents exist in the domain of treating parasitic infestations, some of which have expired. For instance, patents like US7030095 and US6063771, which focused on pediculicidal and ovacidal treatments, have expired, indicating a shift in the patent landscape towards newer, more effective treatments[1].
Competitors and Market Impact
The issuance of this patent positions Merck Sharp & Dohme Corp. as a leader in the treatment of cutaneous mite infestations. Competitors may need to develop alternative treatments or negotiate licensing agreements to remain competitive in the market.
Patent Analytics and Claim Coverage
Claim Coverage Matrix
To fully understand the protection offered by this patent, a Claim Coverage Matrix can be used. This tool categorizes patents by claims and scope concepts, helping to identify gaps or opportunities in the patent landscape. It ensures that all aspects of the technology are protected and highlights areas for future development[3].
Claim Charts
Interactive claim charts generated by tools like ClaimScape® can facilitate a detailed review of the patent coverage with technical experts. These charts help in identifying whether specific scope concepts are applicable to target products or methods, ensuring that the patent claims are aligned with the company's strategic goals[3].
Economic and Strategic Implications
Market Dominance
The exclusive rights granted by this patent allow Merck Sharp & Dohme Corp. to dominate the market for treatments against cutaneous mites. This dominance can lead to significant revenue and market share.
Licensing and Collaboration
The patent can also serve as a bargaining chip for licensing agreements or collaborations with other pharmaceutical companies. This can expand the reach of the treatment and foster innovation in related fields.
Regulatory and Legal Considerations
Patent Enforcement
To maintain the exclusivity of the invention, Merck Sharp & Dohme Corp. must actively enforce the patent against any potential infringers. This involves monitoring the market for unauthorized use and taking legal action when necessary[5].
Global Dossier
For international protection, the Global Dossier service provided by the USPTO can be utilized. This service allows access to file histories of related applications from participating IP Offices, facilitating global patent management[4].
Conclusion
United States Patent 9,895,388 represents a significant advancement in the treatment of cutaneous mite infestations. The detailed analysis of its scope and claims highlights the innovative methods and compositions it introduces. Understanding the patent landscape and leveraging tools like Claim Coverage Matrix and claim charts are crucial for maximizing the value of this patent.
Key Takeaways
- Patent Expiry: November 2033
- Scope: Methods and compositions for controlling cutaneous mites
- Claims: Cover specific formulations, treatment protocols, and therapeutic applications
- Patent Landscape: Positions Merck Sharp & Dohme Corp. as a leader in the field
- Economic Implications: Potential for market dominance and significant revenue
- Regulatory Considerations: Active enforcement and global dossier management are essential
FAQs
Q: What is the primary focus of United States Patent 9,895,388?
A: The primary focus is on methods and compositions useful for controlling cutaneous mites, such as scabies and mange.
Q: When does the patent expire?
A: The patent is set to expire in November 2033.
Q: What are the key components of the patent?
A: The key components include specific active ingredients, formulations (e.g., creams, ointments, oral tablets), and administration methods.
Q: How does the patent impact the market?
A: The patent positions Merck Sharp & Dohme Corp. as a leader in the treatment of cutaneous mite infestations, potentially leading to market dominance and significant revenue.
Q: What tools can be used to analyze the patent claims?
A: Tools like Claim Coverage Matrix and interactive claim charts generated by ClaimScape® can be used to analyze and manage the patent claims effectively.
Sources
- Pharsight: Natroba patent expiration - Pharsight
- USPTO: Patent Claims Research Dataset
- SLWIP: Patent Analytics | Intellectual Property Law
- USPTO: Search for patents - USPTO
- IPLaw: Patent Office Issues 180 Patents To Indiana Citizens in February 2018
